AN2 Therapeutics, Inc.

NasdaqGS:ANTX 株式レポート

時価総額:US$38.8m

AN2 Therapeutics マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Eric Easom

最高経営責任者

US$3.3m

報酬総額

CEO給与比率17.2%
CEO在任期間5yrs
CEOの所有権4.1%
経営陣の平均在職期間5yrs
取締役会の平均在任期間4.8yrs

経営陣の近況

Recent updates

We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Nov 21
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?

Jul 04
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Dec 05
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Aug 20
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

May 09
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Feb 03
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

Oct 21
We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

AN2 Therapeutics secures $17.8M contract from NIH

Sep 29

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Jul 01
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

CEO報酬分析

AN2 Therapeutics の収益と比較して、Eric Easom の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$66m

Dec 31 2023US$3mUS$575k

-US$65m

Sep 30 2023n/an/a

-US$60m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$49m

Dec 31 2022US$3mUS$481k

-US$43m

Sep 30 2022n/an/a

-US$40m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$2mUS$377k

-US$28m

報酬と市場: Ericの 総報酬 ($USD 3.34M ) は、 US市場 ($USD 653.78K ) の同規模の企業の平均を上回っています。

報酬と収益: Ericの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Eric Easom (56 yo)

5yrs

在職期間

US$3,342,848

報酬

Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc. and has been its CEO, President & Director from November 19, 2019 and is its Chairman of the Board since June 2024. He served as Senior Director of...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Eric Easom
Co-Founder5yrsUS$3.34m4.06%
$ 1.6m
Joseph Zakrzewski
Co-Founder & Chairman of the Board7.5yrsUS$179.64k1.69%
$ 655.3k
Lucy Day
CFO, Principal Financial Officer & Principal Accounting Officer5yrsUS$1.52m0.010%
$ 4.1k
George Talbot
Co-Founder & Senior Clinical Advisorno dataデータなしデータなし
Michael R. Alley
Co-Founder & Head of Biologyno dataデータなしデータなし
Joshua Eizen
Chief Legal Officer2.2yrsUS$1.66mデータなし
Sanjay Chanda
Chief Development Officer5yrsデータなし0.0025%
$ 954.4
Stephen Prior
Chief Strategy Officerno dataデータなし0.026%
$ 10.0k

5.0yrs

平均在職期間

60.5yo

平均年齢

経験豊富な経営陣: ANTXの経営陣は経験豊富で経験豊富です(平均在職期間は5年)。


取締役

名称ポジション在職期間報酬所有権
Eric Easom
Co-Founder5yrsUS$3.34m4.06%
$ 1.6m
Joseph Zakrzewski
Co-Founder & Chairman of the Board7.5yrsUS$179.64k1.69%
$ 655.3k
Melvin Spigelman
Independent Director2.8yrsUS$145.64k0%
$ 0
Patricia Martin
Independent Director3.6yrsUS$153.14k0%
$ 0
Margaret FitzPatrick
Lead Independent Director2.5yrsUS$142.14k0%
$ 0
Robin Readnour
Independent Director5yrsUS$146.14k0%
$ 0
Stephanie Wong
Independent Director3.6yrsUS$157.14k0%
$ 0
Kabeer Aziz
Independent Director5yrsUS$145.64k0%
$ 0
Gilbert Marks
Independent Director4.8yrsUS$145.64k0.076%
$ 29.7k

4.8yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: ANTXの 取締役会経験豊富 であると考えられます ( 4.8年の平均在任期間)。